National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Kidney and Renal Pelvis Cancer. Available at: https://seer.cancer.gov/statfacts/html/kidrp.html. Accessed May 29, 2023.

National Cancer Institute. Annual Report to the Nation 2022: Overall Cancer Statistics. Surveillance, Epidemiology, and End Results Program. Available at: https://seer.cancer.gov/report_to_nation/statistics.html. Accessed June 23, 2023.

Kim SH, Park B, Hwang EC, Hong S, Jeong CW, Kwak C, et al. Retrospective multicenter long-term follow-up analysis of prognostic risk factors for recurrence-free, metastasis-free, cancer-specific, and overall survival after curative nephrectomy in non-metastatic renal cell carcinoma. Front Oncol. 2019;9:859.

Article  PubMed  PubMed Central  Google Scholar 

National Cancer Institute. Financial Burden of Cancer Care. Cancer Trends Progress Report. 2022; Available at: https://progressreport.cancer.gov/after/economic_burden. Accessed June 23, 2023.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):e177–232.

Article  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney cancer, version 3.2022, Nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(1):71–90.

Article  PubMed  PubMed Central  Google Scholar 

Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014(1):406960.

PubMed  PubMed Central  Google Scholar 

Haase VH. Inflammation and hypoxia in the kidney: friends or foes? Kidney Int. 2015;88(2):213–5.

Article  PubMed  PubMed Central  Google Scholar 

Chuang Y, Yu M, Huang S, Yang C, Chen C, Lo Y, et al. Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case–control study. J Hypertens. 2017;35(1):170–7.

Article  CAS  PubMed  Google Scholar 

Colt JS, Hofmann JN, Schwartz K, Chow W, Graubard BI, Davis F, et al. Antihypertensive medication use and risk of renal cell carcinoma. Cancer Causes Control. 2017;28(4):289–97.

Article  PubMed  PubMed Central  Google Scholar 

Kristensen KB, Habel LA, Gagne JJ, Friis S, Andersen KK, Hallas J, et al. Risk of renal cell carcinoma associated with calcium channel blockers: A nationwide observational study focusing on confounding by indication. Epidemiology. 2020;31(6):860–71.

Article  PubMed  Google Scholar 

Kim CS, Han K, Choi HS, Bae EH, Ma SK, Kim SW. Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study. Hypertension. 2020;75(6):1439–46.

Article  CAS  PubMed  Google Scholar 

Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS, et al. Medication use and kidney cancer risk: A population-based study. Eur J Cancer. 2017;83:203–10.

Article  PubMed  Google Scholar 

Weinmann S, Glass AG, Weiss NS, Psaty BM, Siscovick DS, White E. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol. 1994;140(9):792–804.

Article  CAS  PubMed  Google Scholar 

Xie Y, Xu P, Wang M, Zheng Y, Tian T, Yang S, et al. Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis. Aging. 2020;12(2):1545.

Article  PubMed  PubMed Central  Google Scholar 

Walther T, Menrad A, Orzechowski H, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J. 2003;17(14):2061–7.

Article  CAS  PubMed  Google Scholar 

Whitfield JF. Calcium signals and cancer. Crit Rev Oncog. 1992;3(1–2):55–90.

CAS  PubMed  Google Scholar 

Gold B, Mirvish SS. N-Nitroso derivatives of hydrochlorothiazide, niridazole, and tolbutamide. Toxicol Appl Pharmacol. 1977;40(1):131–6.

Article  CAS  PubMed  Google Scholar 

Asar SH, Jalalpour SH, Ayoubi F, Rahmani MR, Rezaeian M. PRISMA; preferred reporting items for systematic reviews and meta-analyses. J Rafsanjan Univ Med Sci. 2016;15(1):68–80.

Google Scholar 

Matsui S, Sobue T, Zha L, Kitamura T, Sawada N, Iwasaki M, et al. Long-term antihypertensive drug use and risk of cancer: the Japan public health Center‐based prospective study. Cancer Sci. 2021;112(5):1997–2005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colt JS, Schwartz K, Graubard BI, Davis F, Ruterbusch J, DiGaetano R et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011:797–804.

Schouten LJ, van Dijk BA, Oosterwijk E, Hulsbergen-van de Kaa CA, Kiemeney LA, Goldbohm RA, et al. Hypertension, antihypertensives and mutations in the von Hippel–Lindau gene in renal cell carcinoma: results from the Netherlands cohort study. J Hypertens. 2005;23(11):1997–2004.

Article  CAS  PubMed  Google Scholar 

Braun S, Boyko V, Behar S, Reicher-Reiss H, Laniado S, Kaplinsky E, et al. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. J Am Coll Cardiol. 1998;31(4):804–8.

Article  CAS  PubMed  Google Scholar 

Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst. 1986;77(2):351–6.

CAS  PubMed  Google Scholar 

Prineas RJ, Folsom AR, Zhang ZM, Sellers TA, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology. 1997;8(1):31–6.

Article  CAS  PubMed  Google Scholar 

Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol. 2017;83(3):653–63.

Article  CAS  PubMed  Google Scholar 

McCredie M, Stewart JH. Risk factors for kidney cancer in new South wales, australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control. 1992;3:323–31.

Article  CAS  PubMed  Google Scholar 

Greenland S, Thomas DC, Morgenstern H. The rare-disease assumption revisited. A critique of estimators of relative risk for case-control studies. Am J Epidemiol. 1986;124(6):869–83.

Article  CAS  PubMed  Google Scholar 

Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa scale. World J Meta-Analysis. 2017;5(4):80–4.

Article  Google Scholar 

Stanley TD, Jarrell SB. Meta-regression analysis: a quantitative method of literature surveys. J Economic Surveys. 2005;19(3):299–308.

Article  Google Scholar 

Greenland S, Longnecker MP. Methods for trend Estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135(11):1301–9.

Article  CAS  PubMed  Google Scholar 

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med. 2001;20(4):641–54.

Article  CAS  PubMed  Google Scholar 

Tipton E. Small sample adjustments for robust variance Estimation with meta-regression. Psychol Methods. 2015;20(3):375.

Article  PubMed  Google Scholar 

Hedges LV, Tipton E, Johnson MC. Robust variance Estimation in meta-regression with dependent effect size estimates. Res Synthesis Methods. 2010;1(1):39–65.

Article  Google Scholar 

Chang P, Huang W, Lin C, Huang T, Wu Y, Chen J et al. Propranolol reduces cancer risk: a population-based cohort study. Medicine 2015;94(27).